Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

Share Price is delayed by 15 minutes
Get Live Data
7,130.00    80.00 (1.13%)
Bid:
7,110.00
Ask:
7,120.00
Spread: 10.00 (0.141%)
Market Cap: £9.56b
DPLM Live PriceLast checked at - London Stock Exchange

Intraday Diploma Share Chart

Interim Management Statement

14 Jan 2009 07:00

RNS Number : 5894L
Diploma PLC
14 January 2009
 



<>

12 CHARTERHOUSE SQUARE, LONDON EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20 7549 5715

FOR IMMEDIATE RELEASE

14 January 2009

DIPLOMA PLC

INTERIM MANAGEMENT STATEMENT

Diploma PLC, the international group of businesses supplying specialised technical products and services, is today issuing its first Interim Management Statement of the new financial yearahead of the Company's AGM to be held today at Brewers Hall, Aldermanbury SquareLondon, EC2V 7HR at 12.00 midday. This Statement relates to the period from 1 October 2008 to 31 December 2008 and includes the first quarter's trading.

The Group continues to benefit from its focus on specialised sectors and supplying essential products and services which are mostly funded by customers' operating, rather than capital, budgets.  With more than 60% of revenues generated outside the UK, the Group has also gained on translation from the significant deterioration in the value of UK sterling relative to all other major currencies. With this background, the Board is able to report an increase in Group revenues of 2% over the comparable period last year although, on a constant currency basis, Group revenues reduced by 7% over the comparable period.

In Life Sciences, the Canadian Healthcare businesses, which account for over 50% of sector revenue, continued to show steady development.  Revenue from the European businesses were somewhat reduced against a strong comparable quarter last year.

Trading in the US Seals businesses weakened in the quarter, reflecting the difficult market conditions in the broader US industrial economy. Cost reduction programmes implemented in the US operations have partly mitigated the effects of reduced operational leverage. By contrast, the performance of the European Seals businesses was strong.

In Controls, the European businesses overall delivered a steady performance, with a continued focus on relatively more buoyant, technically driven sectors. 

The deterioration in the value of UK sterling relative to all other major currencies has had a significant positive impact on the Group's results on translation. Against the comparable period last year, the US dollarthe Euro and the Canadian dollar have appreciated by 25%, 16% and 6% respectively against UK sterling. Conversely at a transaction level, the weakness of UK sterling and the deterioration of the Canadian dollar relative to the US dollar, has put pressure on gross margins in the UK and Canadian businesses, by increasing the cost of goods sold.

The Group continued to maintain a strong financial position with cash balances of £16.6m at 31 December 2008 and undrawn committed term facilities of £25.0m.

On 23 December 2008, the Group announced that it had signed contracts to acquire RT/Dygerta leading supplier of seals, o-rings and custom moulded and machine parts, based in the US, for a maximum consideration of £13.2m (US$19.75m). This acquisition formally closed on 12 January 2009 and the initial consideration paid of £9.6m (US$14.4m) has been funded in part from the Group's existing cash resources and in part by drawing down £4.7m (US$7.0m) from the Group's committed bank facility. This acquisition is expected to be immediately earnings enhancing for the Group.

In addition, as reported in the 2008 Annual Report, on 5 November 2008, the Group acquired Meditech, a small medical diagnostic company in Canada for a maximum consideration of £1.5m (C$2.9m). On completion, the initial consideration of £1.3m (C$2.4m) was funded out of the Group's existing cash resources.

Finally, pursuant to the sale and purchase agreement signed on 28 August 2007, the Group will shortly be making a payment to the vendors of AMT of £1.1m (C$2.0m) as deferred consideration. This payment was based on the performance of that business during the year ended 30 September 2008.

There have been no other significant changes in the position of the Group in the period since the publication of the Annual Report for the year ended 30 September 2008.

The next update on trading is expected to be issued as part of the Half Year results for the six months ending 31 March 2009, which are expected to be released on 11 May 2009.

Notes:

This Interim Management Statement, which is based upon unaudited management accounts, has been prepared solely to provide additional information to the shareholders of Diploma PLC in order to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules. It should not be relied on by any other party, for other purposes.

A copy of this Statement, together with further information about Diploma PLC, may be viewed on its website at www.diplomaplc.com

For further enquiries please contact:

Bruce Thompson, Chief Executive Officer

020 7549 5700

Nigel Lingwood, Group Finance Director

020 7549 5705

Simon Bloomfield, Bankside Consultants

020 7367 8861

NOTE TO EDITORS:

Diploma PLC is an international group of businesses supplying specialised technical products and services to the Life Sciences, Seals and Controls industries.

Diploma achieves stable growth and attractive margins from its focus on supplying specialised technical products to markets which value high levels of customer service, technical support and value adding activities. A high proportion of revenues are generated from essential products and services funded by operating, rather than capital budgets.

The Group employs ca. 1,000 employees and its principal operating businesses are located in the UKGermany, US and Canada.

Over the last five years, the Group has grown adjusted earnings per share at an average of ca. 21% p.a. through a combination of organic growth and acquisitions. The current market capitalisation is ca. £150m.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAXFDFSFNEFE
Date   Source Headline
16th Jan 202010:40 amRNSResult of AGM
15th Jan 20207:00 amRNSTrading Statement
24th Dec 20197:00 amRNSDirector / PDMR Grant of LTIP Award
23rd Dec 20197:00 amRNSDirectorate Change
17th Dec 20195:09 pmRNSHolding(s) in Company
16th Dec 201912:00 pmRNSHolding(s) in Company
6th Dec 20193:27 pmRNSAnnual Financial Report & Notice of AGM
21st Nov 20194:00 pmRNSDirector/PDMR Shareholding
18th Nov 20197:00 amRNSFinal Results
8th Oct 20197:00 amRNSDirectorate Change
25th Sep 20197:00 amRNSAcquisition
10th Sep 20194:49 pmRNSHolding(s) in Company
28th Aug 20197:00 amRNSTrading Statement
8th Aug 20193:00 pmRNSHolding(s) in Company
17th Jul 20191:01 pmRNSHolding(s) in Company
11th Jul 20197:00 amRNSAcquisition
13th Jun 20192:00 pmRNSDirector Declaration
13th May 20197:00 amRNSHalf-year Report
1st Apr 20197:00 amRNSAppointment of Joint Corporate Broker
27th Mar 20197:00 amRNSHalf Year Trading Update
26th Feb 20197:00 amRNSDirector/PDMR Shareholding
25th Feb 20194:00 pmRNSDirector/PDMR Shareholding
25th Feb 20197:00 amRNSDirectorate Appointments
29th Jan 20193:30 pmRNSDirector/PDMR Shareholding
16th Jan 20194:19 pmRNSResult of AGM
16th Jan 20197:01 amRNSDirectorate Change
16th Jan 20197:00 amRNSTrading Statement
7th Dec 20184:09 pmRNSDirector/PDMR Shareholding
7th Dec 20183:00 pmRNSAnnual Financial Report & Notice of AGM
27th Nov 20184:26 pmRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSFinal Results
12th Oct 20187:00 amRNSAcquisition
3rd Sep 20184:45 pmRNSBoard Committee Change
29th Aug 20187:01 amRNSDirectorate Change
29th Aug 20187:00 amRNSTrading Statement
22nd Aug 20187:00 amRNSAcquisition
10th Jul 20181:46 pmRNSHolding(s) in Company
12th Jun 20182:59 pmRNSHolding(s) in Company
16th May 20182:41 pmRNSDirector Declaration
15th May 20184:20 pmRNSDirector/PDMR Shareholding
15th May 20184:09 pmRNSDirector/PDMR Shareholding
14th May 20187:00 amRNSHalf-year Report
9th May 20187:00 amRNSDirectorate Change
23rd Apr 20187:00 amRNSDirectorate Change
28th Mar 20187:00 amRNSTrading Update
21st Mar 20189:30 amRNSHolding(s) in Company
20th Mar 20184:00 pmRNSHolding(s) in Company
6th Feb 20189:49 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSDirectorate Change
23rd Jan 20184:00 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.